Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)
Primary Purpose
Obesity, Overweight
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Reduced energy (lite) OJ fortified with Calcium and Vitamin D
Nutrition Counseling
Reduced energy (lite) OJ without Calcium and Vitamin D
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Calcium, Vitamin D, Weight Loss, Overweight, Obesity, Lite Orange Juice
Eligibility Criteria
Inclusion Criteria:
- Men or women, between 18 and 65 years of age, who are capable of providing informed consent.
- BMI of 25 to 35 kg/m2.
- Non-smoker (for at least 6 months).
- In good health, as determined by the principal investigator based on medical history and physical examination.
- Clinical laboratory evaluations (including Biochemistry, Hematology, Endocrinology) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator.
- Because of the calorie-restricted diet and radiation exposure from the CT scan, females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile for at least 3 months, or be willing to use an approved method of contraception (which may include use of abstinence; intrauterine device; female condom with spermicide; diaphragm with spermicide; cervical cap with spermicide; oral or transdermal hormonal contraceptives; a condom with spermicide by the sexual partner; or a sterile sexual partner) from 35 days prior to study entry (i.e., Day -1) until 30 days following Study Completion. For all females, the pregnancy test result must be negative at the screening visit and at visits when a CT scan will be done.
- Ability to comprehend and willingness to sign the Informed Consent Form for this study.
- Ability to comply with study restrictions regarding diet and exercise.
- Stable weight (+ 5%) for at least 3 months prior to study entry.
Exclusion Criteria:
- Diabetes mellitus.
- History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject.
- Participation in any other investigational diet study within 90 days prior to study entry.
- History of a medical or psychological condition or social circumstances that would impair the subject's ability to participate reliably in the study.
- Use within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. (see Appendix 1 for detailed list)
- Active eating disorder.
- History of alcoholism or substance abuse within 5 years prior to study entry.
- Recommendation by a physician to avoid calcium supplements because of a history of kidney stones or other medical condition.
- History of hyperparathyroidism or sarcoidosis.
- Osteoporosis or other medical condition for which a physician has recommended taking a multivitamin or calcium supplementation.
- High calcium intake (more than 2 servings of dairy products per day or taking calcium supplements > 3x/wk ) for 1 month prior to study start date and for duration of study. (If participant is taking calcium supplement > 3x/wk or more than 2 servings of dairy products per day, they are eligible to participate if they agree to stop for 1 month prior to study start date and for the duration of the study. Participants will similarly be asked to stop multivitamins as the majority of these supplements contain calcium.)
- General medical conditions that are well-controlled will not be a basis for exclusion in the study. Subjects with uncontrolled conditions that are not adequately controlled or that might pose an unacceptable risk for participation, as clinically determined by the investigators, will be excluded.
Sites / Locations
- Massachusetts General Hospital Weight Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Lite OJ with Ca and VitD
Lite OJ without Ca and VitD
Arm Description
240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
240ml of reduced energy (lite) OJ beverage, 3 times per day.
Outcomes
Primary Outcome Measures
Change in body weight
Secondary Outcome Measures
Change in visceral adipose tissue mass
Change in subcutaneous adipose tissue mass
Full Information
NCT ID
NCT00386672
First Posted
October 6, 2006
Last Updated
January 9, 2017
Sponsor
Massachusetts General Hospital
Collaborators
The Beverage Institute for Health and Wellness
1. Study Identification
Unique Protocol Identification Number
NCT00386672
Brief Title
Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)
Official Title
Calcium Supplementation for a Healthy Weight- LITE
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
December 2006 (Actual)
Study Completion Date
December 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
The Beverage Institute for Health and Wellness
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to find out if taking calcium and vitamin D supplements, while following a low-calorie diet, can help people lose weight.
Detailed Description
Recent studies suggest that calcium may be important for weight loss, but other studies have not had the same results. The purpose of the study is to find out if taking calcium and vitamin D supplements, while following a low-calorie diet, can help people lose weight.
We will use special orange juice with less calories than regular orange juice. Half of the subjects in this study will drink the study juice (reduced-calorie orange juice) containing extra calcium and vitamin D. The other subjects will drink reduced-calorie orange juice without any extra calcium or vitamin D in it.
Comparisons: We will compare subjects who follow the diet and take calcium and vitamin D supplements to those who only follow the diet.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight
Keywords
Calcium, Vitamin D, Weight Loss, Overweight, Obesity, Lite Orange Juice
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
83 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lite OJ with Ca and VitD
Arm Type
Experimental
Arm Description
240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
Arm Title
Lite OJ without Ca and VitD
Arm Type
Active Comparator
Arm Description
240ml of reduced energy (lite) OJ beverage, 3 times per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Reduced energy (lite) OJ fortified with Calcium and Vitamin D
Other Intervention Name(s)
Minute Maid Light Orange Juice
Intervention Description
Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
Intervention Type
Behavioral
Intervention Name(s)
Nutrition Counseling
Intervention Description
Individual and group nutritional counseling by a registered dietician.
Intervention Type
Dietary Supplement
Intervention Name(s)
Reduced energy (lite) OJ without Calcium and Vitamin D
Other Intervention Name(s)
Minute Maid Light Orange Juice
Intervention Description
Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
Primary Outcome Measure Information:
Title
Change in body weight
Time Frame
Baseline and at 16 weeks
Secondary Outcome Measure Information:
Title
Change in visceral adipose tissue mass
Time Frame
Baseline and at 16 weeks
Title
Change in subcutaneous adipose tissue mass
Time Frame
Baseline and at 16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men or women, between 18 and 65 years of age, who are capable of providing informed consent.
BMI of 25 to 35 kg/m2.
Non-smoker (for at least 6 months).
In good health, as determined by the principal investigator based on medical history and physical examination.
Clinical laboratory evaluations (including Biochemistry, Hematology, Endocrinology) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator.
Because of the calorie-restricted diet and radiation exposure from the CT scan, females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile for at least 3 months, or be willing to use an approved method of contraception (which may include use of abstinence; intrauterine device; female condom with spermicide; diaphragm with spermicide; cervical cap with spermicide; oral or transdermal hormonal contraceptives; a condom with spermicide by the sexual partner; or a sterile sexual partner) from 35 days prior to study entry (i.e., Day -1) until 30 days following Study Completion. For all females, the pregnancy test result must be negative at the screening visit and at visits when a CT scan will be done.
Ability to comprehend and willingness to sign the Informed Consent Form for this study.
Ability to comply with study restrictions regarding diet and exercise.
Stable weight (+ 5%) for at least 3 months prior to study entry.
Exclusion Criteria:
Diabetes mellitus.
History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject.
Participation in any other investigational diet study within 90 days prior to study entry.
History of a medical or psychological condition or social circumstances that would impair the subject's ability to participate reliably in the study.
Use within the last six months of medications that can result in significant weight gain or weight loss, including antipsychotics, selective serotonin reuptake inhibitors, anti-epileptic drugs, appetite-suppressants such as phentermine and sibutramine, and the lipase-inhibitor orlistat. (see Appendix 1 for detailed list)
Active eating disorder.
History of alcoholism or substance abuse within 5 years prior to study entry.
Recommendation by a physician to avoid calcium supplements because of a history of kidney stones or other medical condition.
History of hyperparathyroidism or sarcoidosis.
Osteoporosis or other medical condition for which a physician has recommended taking a multivitamin or calcium supplementation.
High calcium intake (more than 2 servings of dairy products per day or taking calcium supplements > 3x/wk ) for 1 month prior to study start date and for duration of study. (If participant is taking calcium supplement > 3x/wk or more than 2 servings of dairy products per day, they are eligible to participate if they agree to stop for 1 month prior to study start date and for the duration of the study. Participants will similarly be asked to stop multivitamins as the majority of these supplements contain calcium.)
General medical conditions that are well-controlled will not be a basis for exclusion in the study. Subjects with uncontrolled conditions that are not adequately controlled or that might pose an unacceptable risk for participation, as clinically determined by the investigators, will be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lee M Kaplan, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital Weight Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
10546691
Citation
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999 Oct 27;282(16):1523-9. doi: 10.1001/jama.282.16.1523.
Results Reference
background
PubMed Identifier
9545015
Citation
Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998 Mar;6(2):97-106. doi: 10.1002/j.1550-8528.1998.tb00322.x.
Results Reference
background
PubMed Identifier
11134120
Citation
Davies KM, Heaney RP, Recker RR, Lappe JM, Barger-Lux MJ, Rafferty K, Hinders S. Calcium intake and body weight. J Clin Endocrinol Metab. 2000 Dec;85(12):4635-8. doi: 10.1210/jcem.85.12.7063.
Results Reference
background
PubMed Identifier
12791622
Citation
Jacqmain M, Doucet E, Despres JP, Bouchard C, Tremblay A. Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. Am J Clin Nutr. 2003 Jun;77(6):1448-52. doi: 10.1093/ajcn/77.6.1448.
Results Reference
background
PubMed Identifier
11999543
Citation
Zemel MB. Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr. 2002 Apr;21(2):146S-151S. doi: 10.1080/07315724.2002.10719212.
Results Reference
background
PubMed Identifier
10834935
Citation
Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary calcium. FASEB J. 2000 Jun;14(9):1132-8.
Results Reference
background
PubMed Identifier
11606486
Citation
Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha,25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J. 2001 Dec;15(14):2751-3. doi: 10.1096/fj.01-0584fje. Epub 2001 Oct 15.
Results Reference
background
PubMed Identifier
12733746
Citation
Zemel MB. Role of dietary calcium and dairy products in modulating adiposity. Lipids. 2003 Feb;38(2):139-46. doi: 10.1007/s11745-003-1044-6.
Results Reference
background
PubMed Identifier
11156940
Citation
Shi H, Dirienzo D, Zemel MB. Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice. FASEB J. 2001 Feb;15(2):291-3. doi: 10.1096/fj.00-0584fje. Epub 2000 Dec 8.
Results Reference
background
PubMed Identifier
11454514
Citation
Ye WZ, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. Eur J Endocrinol. 2001 Aug;145(2):181-6. doi: 10.1530/eje.0.1450181.
Results Reference
background
PubMed Identifier
7584878
Citation
Barger-Lux MJ, Heaney RP, Hayes J, DeLuca HF, Johnson ML, Gong G. Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. Calcif Tissue Int. 1995 Aug;57(2):161-2. doi: 10.1007/BF00298438.
Results Reference
background
PubMed Identifier
2991340
Citation
Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest. 1985 Jul;76(1):370-3. doi: 10.1172/JCI111971.
Results Reference
background
PubMed Identifier
3145124
Citation
Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcif Tissue Int. 1988 Oct;43(4):199-201. doi: 10.1007/BF02555135.
Results Reference
background
PubMed Identifier
12223452
Citation
Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes. FASEB J. 2002 Nov;16(13):1808-10. doi: 10.1096/fj.02-0255fje. Epub 2002 Sep 5.
Results Reference
background
PubMed Identifier
15231722
Citation
Sun X, Zemel MB. Role of uncoupling protein 2 (UCP2) expression and 1alpha, 25-dihydroxyvitamin D3 in modulating adipocyte apoptosis. FASEB J. 2004 Sep;18(12):1430-2. doi: 10.1096/fj.04-1971fje. Epub 2004 Jul 1.
Results Reference
background
PubMed Identifier
15141427
Citation
Zemel MB, Miller SL. Dietary calcium and dairy modulation of adiposity and obesity risk. Nutr Rev. 2004 Apr;62(4):125-31. doi: 10.1111/j.1753-4887.2004.tb00034.x.
Results Reference
background
PubMed Identifier
12586999
Citation
Melanson EL, Sharp TA, Schneider J, Donahoo WT, Grunwald GK, Hill JO. Relation between calcium intake and fat oxidation in adult humans. Int J Obes Relat Metab Disord. 2003 Feb;27(2):196-203. doi: 10.1038/sj.ijo.802202.
Results Reference
background
PubMed Identifier
11966382
Citation
Pereira MA, Jacobs DR Jr, Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA. 2002 Apr 24;287(16):2081-9. doi: 10.1001/jama.287.16.2081.
Results Reference
background
PubMed Identifier
11999544
Citation
Heaney RP, Davies KM, Barger-Lux MJ. Calcium and weight: clinical studies. J Am Coll Nutr. 2002 Apr;21(2):152S-155S. doi: 10.1080/07315724.2002.10719213.
Results Reference
background
PubMed Identifier
22170363
Citation
Rosenblum JL, Castro VM, Moore CE, Kaplan LM. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr. 2012 Jan;95(1):101-8. doi: 10.3945/ajcn.111.019489. Epub 2011 Dec 14.
Results Reference
background
Learn more about this trial
Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)
We'll reach out to this number within 24 hrs